Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4

Daniel H Palmer¹, Richard J Jackson¹, Christoph Springfeld¹+3

• ¹Daniel H. Palmer, PhD and Richard J. Jackson, PhD, University of Liverpool, Liverpool, United Kingdom; Christoph Springfeld, MD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Thilo Hackert, MD, Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Christoph W. Michalski, MD and John P. Neoptolemos, MD, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.